Available by prescription only, Eloxatin® (oxaliplatin) is licensed to treat advanced colorectal cancer and stage III colon cancer (after surgery to remove the tumor) in adults. It comes as an intravenous (IV) injection that is administered by your healthcare provider every two weeks.
Eloxatin is a type of platinum-based anticancer drug. It works by binding together strands of DNA within the cells, including cancer cells. This prevents the cells from multiplying, which can stop the growth and spread of the cancer.
Before starting chemotherapy treatment with Eloxatin, make sure to review the medication's safety information with your healthcare provider. For example, you may not be able to use this medicine if you have certain allergies, are taking certain other medications, or are pregnant or breastfeeding.
(For more information on this chemotherapy drug, click Eloxatin. This article offers a complete overview, including in-depth dosing guidelines, possible side effects, and more.)
Eloxatin Web site. Available at: http://www.eloxatin.com/. Accessed January 12, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed January 12, 2012.
sanofi-aventis Press Release. sanofi-aventis announces settlement of Eloxatin U.S. patent litigation. April 1, 2010.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click